Grant: Doctoral: Vanier Canada Graduate Scholarships
University of Toronto
$150,000.00
Leptin action in a gut-brain axis and involvement in the glucose-lowering effect of duodenal-jejunal bypass surgery
FY 2012-13
Summary
Diabetes and obesity are characterized by a disruption in glucose homeostasis due partly to an elevation in hepatic glucose production. Thus, it is important to understand the mechanism(s) involved. The peptide hormone leptin has been shown to regulate glucose production and food intake by binding to its receptor in the brain, however leptin receptors are also located in the jejunum and it is unknown whether jejunal leptin action has a similar role. Furthermore, gastric duodenal bypass surgery (GBS) lowers blood glucose prior to weight loss in diabetes and obesity, but the possible role of leptin remains unclear. Since leptin is produced in the stomach, in addition to adipose tissue, and leptin receptors are located in the jejunum, and GBS enhances digestive flow from the stomach into the jejunum, increased leptin action in the jejunum may contribute to the glucose-lowering effect of GBS in diabetes. Therefore, our objective is to evaluate whether the jejunum senses leptin to lower glucose production and whether the mechanism(s) involved are enhanced in GBS to lower blood glucose. Leptin will be infused into the jejunum of rodents, and glucose production will be measured using established techniques. To examine the underlying mechanisms, inhibitors of signaling molecules and neuronal transmission to the brain and liver will be infused along with leptin. Leptin will also be infused into the jejunum of diabetic rats to determine its effectiveness in the diseased state. If leptin's effect remains, GBS will be performed in rats with diabetes, followed by jejunal infusion experiments with the same inhibitors that were found to be effective in negating jejunal leptin sensing. These findings will reveal a novel site of leptin's metabolic action and possible new therapeutic strategies, other than GBS which is very invasive, targeting the jejunum to lower glucose levels in diabetes and obesity.
Department
Program
Doctoral: Vanier Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
274460
Name
Rasmussen Brittany A
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Nutrition, Metabolism and Diabetes
Theme2
Biomedical
Prcname2
Vanier Canada Graduate Scholarships CIHR
Projecttitle
Leptin action in a gut-brain axis and involvement in the glucose-lowering effect of duodenal-jejunal bypass surgery
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$150,000
Cihrequipment2
$0
Programname2
Doctoral: Vanier Canada Graduate Scholarships
Keyworddelim
Adenovirus; Diabetic Animal Model; Gastric Bypass Surgery; Glucose Metabolism; Glucose Production; Gut-Brain-Liver Axis; Hormone Action; Intestinal Signaling; Leptin; Pancreatic Glucose/Insulin Clamp
Abstract
Diabetes and obesity are characterized by a disruption in glucose homeostasis due partly to an elevation in hepatic glucose production. Thus, it is important to understand the mechanism(s) involved. The peptide hormone leptin has been shown to regulate glucose production and food intake by binding to its receptor in the brain, however leptin receptors are also located in the jejunum and it is unknown whether jejunal leptin action has a similar role. Furthermore, gastric duodenal bypass surgery (GBS) lowers blood glucose prior to weight loss in diabetes and obesity, but the possible role of leptin remains unclear. Since leptin is produced in the stomach, in addition to adipose tissue, and leptin receptors are located in the jejunum, and GBS enhances digestive flow from the stomach into the jejunum, increased leptin action in the jejunum may contribute to the glucose-lowering effect of GBS in diabetes. Therefore, our objective is to evaluate whether the jejunum senses leptin to lower glucose production and whether the mechanism(s) involved are enhanced in GBS to lower blood glucose. Leptin will be infused into the jejunum of rodents, and glucose production will be measured using established techniques. To examine the underlying mechanisms, inhibitors of signaling molecules and neuronal transmission to the brain and liver will be infused along with leptin. Leptin will also be infused into the jejunum of diabetic rats to determine its effectiveness in the diseased state. If leptin's effect remains, GBS will be performed in rats with diabetes, followed by jejunal infusion experiments with the same inhibitors that were found to be effective in negating jejunal leptin sensing. These findings will reveal a novel site of leptin's metabolic action and possible new therapeutic strategies, other than GBS which is very invasive, targeting the jejunum to lower glucose levels in diabetes and obesity.
Competitiondate
201211
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Rasmussen, Brittany A
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $150,000~ $0~